Should bodybuilders routinely test ApoB?

Yes, particularly during oral AAS cycles and when using MK-677 or growth hormone. These scenarios create the discordance conditions under which LDL-C underestimates atherogenic particle burden. Between cycles when metabolic status is normal and triglycerides are low, LDL-C provides adequate monitoring. But during and after oral AAS use, and whenever triglycerides are elevated above 1.5 mmol/L, ApoB provides a more accurate picture of actual cardiovascular risk. ApoB is increasingly available as an add-on to standard lipid panels at private labs.

What ApoB level is concerning for a steroid user?

ApoB above 100 mg/dL warrants attention; above 130 mg/dL is elevated by most guidelines. For context, ESC/EAS 2019 targets ApoB below 100 mg/dL for moderate-risk patients and below 65 mg/dL for very high-risk patients. A steroid user with a history of multiple cycles, elevated triglycerides, or family history of premature cardiovascular disease would be considered higher-risk, and an ApoB consistently above 100 mg/dL on and between cycles represents meaningful long-term atherogenic exposure. The most actionable scenario is discordance: LDL-C in the 70-100 mg/dL range but ApoB above 100 mg/dL, which signals a high-particle-number, small-dense-LDL phenotype that LDL-C alone misses.

Can you have normal LDL but high ApoB?

Yes, and this is exactly the discordance pattern that makes ApoB clinically valuable. When lipoprotein particles are small and dense (driven by elevated triglycerides, insulin resistance, oral AAS, or GH/MK-677 use), each particle carries less cholesterol than a normal-sized particle. The same number of particles, each carrying less cholesterol, produces a lower LDL-C reading while ApoB accurately counts the full particle number. Research consistently shows that when LDL-C and ApoB are discordant, cardiovascular risk tracks with ApoB. A normal LDL-C with elevated ApoB is not reassuring; it means the atherogenic particle burden is higher than LDL-C suggests.

LDL vs ApoB: Which Better Predicts Cardiovascular Risk?

LDL cholesterol measures the cholesterol content carried by LDL particles, while ApoB counts the actual number of atherogenic particles. In steroid users, ApoB is often a more accurate risk predictor because LDL can underestimate particle count when particles are small and dense.

Marker Comparison

Overview

Both LDL-C and ApoB assess atherogenic lipoprotein burden, but they measure fundamentally different things.

LDL-C (LDL cholesterol) quantifies the mass of cholesterol carried within LDL particles. It is the standard metric reported on routine lipid panels and the primary target of most cardiovascular guidelines.

ApoB (apolipoprotein B) counts the number of atherogenic particles directly. Each atherogenic lipoprotein, including every LDL, VLDL, IDL, and Lp(a) particle, carries exactly one ApoB molecule. Measuring ApoB gives a direct count of total atherogenic particle burden, not just LDL.

Why the difference matters: When lipoprotein particles are normal in size, LDL-C and ApoB correlate well and tell the same story. But when particles are small and dense (a pattern common in metabolic syndrome, insulin resistance, high triglycerides, and steroid-induced dyslipidemia), you can have a "normal" LDL-C alongside an elevated ApoB. This condition, called discordance, means LDL-C is systematically underestimating the actual number of atherogenic particles in circulation. Each small dense LDL particle carries less cholesterol per particle than a large buoyant LDL, so the same number of particles produces a lower LDL-C reading while maintaining the same atherogenic particle count as measured by ApoB.

Side-by-Side Comparison

Attribute	LDL	ApoB
What it measures	Cholesterol mass within LDL particles	Count of all atherogenic lipoprotein particles
Units	mg/dL or mmol/L	mg/dL or nmol/L
Optimal range (standard risk)	Below 100 mg/dL; below 70 mg/dL for high-risk	Below 100 mg/dL (ESC target: below 80 mg/dL for high-risk)
What it misses	Small dense LDL particles; VLDL and IDL contributions	Nothing: all atherogenic particles carry one ApoB
Better when triglycerides elevated	No: LDL-C underestimates particle count (discordance)	Yes: accurately counts particles regardless of size
Captures Lp(a)	No	Yes: Lp(a) carries one ApoB per particle
Cost	Included in standard lipid panel	Add-on test; additional cost
Guideline support	Primary target in all major guidelines	Secondary target in ESC 2019; increasing emphasis in 2023 updates
Relevance for AAS users	Adequate when triglycerides normal and particles large	Preferred on oral AAS cycles, with MK-677/GH, or when triglycerides elevated
Availability	Universal: every standard lipid panel	Not always included; requires specific order

Key Differences

What each measures:

LDL-C: The mass of cholesterol within LDL particles (mg/dL). An indirect estimate of particle burden when particles are normal-sized.
ApoB: The count of atherogenic particles directly. One ApoB per particle means ApoB in nmol/L is a near-perfect surrogate for total atherogenic particle number.

Scope of particles captured:

LDL-C: Reflects only LDL particles (calculated or directly measured).
ApoB: Reflects all atherogenic particles: LDL, VLDL, IDL, Lp(a), and chylomicron remnants. This makes ApoB a more comprehensive measure of total atherogenic burden.

Behaviour in discordance:

LDL-C: When particles are small and dense (elevated triglycerides, insulin resistance), LDL-C underestimates particle count because each small particle carries less cholesterol.
ApoB: Accurately reflects particle count regardless of particle size. Elevated when particles are small and dense, even if LDL-C appears acceptable.

Relevance to AAS users:

LDL-C: Standard monitoring metric; sufficient when triglycerides are normal.
ApoB: Critical when triglycerides are elevated, when running oral AAS that shift particle size distribution toward small dense LDL, or when insulin resistance is present (e.g., with MK-677 or GH use).

Guidelines support:

LDL-C: Primary target in ACC/AHA 2019 guidelines, all standard clinical protocols.
ApoB: Included as an optional or secondary target in ESC/EAS 2019 guidelines and 2023 ACC/AHA dyslipidemia updates, with increasing emphasis as evidence accumulates.

Cost and availability:

LDL-C: Included in every standard lipid panel; no additional cost.
ApoB: Requires a specific add-on test; increasingly available but not universally included in routine panels.

When to Use Which

Use LDL-C when:

Triglycerides are normal (below 1.5 mmol/L or 130 mg/dL): particle size tends to be normal, so LDL-C and ApoB correlate well
Routine monitoring between cycles when metabolic status is stable
Initial cardiovascular risk screening before more detailed testing

Use ApoB when:

Triglycerides are elevated above 1.5 mmol/L (130 mg/dL): this is the primary clinical trigger for discordance
Running oral AAS cycles, especially compounds known to shift toward small dense LDL (stanozolol, superdrol, oxymetholone)
Using MK-677 or growth hormone, which promote insulin resistance and shift the lipoprotein profile toward small dense particles
On a high-calorie bulking diet with elevated triglycerides
LDL-C appears acceptable but you suspect the particle burden is higher (e.g., LDL-C 90 mg/dL but triglycerides 2.5 mmol/L)
Family history of premature cardiovascular disease despite "normal" LDL-C

Ideal approach:

Test both when you have the option. ApoB provides the fuller picture; LDL-C provides the guideline-concordant metric for statin decisions.
ApoB above 100 mg/dL (approximate equivalent: LDL-C above 2.6 mmol/L) with a "normal" LDL-C is the classic discordance pattern that warrants closer monitoring and potentially earlier intervention.

Clinical Context

Multiple prospective studies have demonstrated that ApoB is a stronger predictor of cardiovascular events than LDL-C, particularly in populations with metabolic syndrome, elevated triglycerides, or discordant LDL-C/ApoB values. The INTERHEART study, AMORIS cohort, and multiple meta-analyses all show that when LDL-C and ApoB are discordant, the cardiovascular risk tracks with ApoB rather than LDL-C. The 2019 ESC/EAS dyslipidemia guidelines were the first major international guidelines to formally include ApoB as a treatment target (below 65 mg/dL for very high-risk patients), reflecting this accumulating evidence. The 2023 ACC/AHA cholesterol guideline update continued to strengthen the case for ApoB in specific high-risk populations. The fundamental principle is: atherosclerotic plaques are initiated and progressed by individual atherogenic particles entering and becoming retained in the arterial wall, so counting particles (ApoB) is more directly mechanistically relevant than measuring the cholesterol load they carry (LDL-C).

Bodybuilder Context

Steroid users frequently develop a pattern that has been called the triad of discordance: elevated triglycerides (from diet, oral AAS, or GH/MK-677 use), insulin resistance (from GH, MK-677, or high-calorie bulking), and a shift toward small dense LDL particles (from oral 17-AA AAS, particularly stanozolol and superdrol). When all three are present, LDL-C systematically underestimates the true atherogenic particle burden. An athlete running Winstrol at 30 mg/day may see their LDL-C rise from 90 to 120 mg/dL, which looks bad but still below clinical intervention thresholds. Their ApoB, however, may have risen to 150 mg/dL or higher because the stanozolol has shifted particles to the small dense phenotype where each particle carries less cholesterol. ApoB captures this completely while LDL-C only partially captures it. Athletes who also use MK-677 for its GH-releasing effects face a compounding problem: MK-677 drives insulin resistance, which independently promotes small dense LDL production. Testing ApoB on oral AAS cycles, especially when triglycerides are also elevated, provides a materially better picture of actual cardiovascular risk than LDL-C alone.

Frequently Asked Questions

LDL

Blood marker details

ApoB

Blood marker details

HDL vs LDL: Understanding Good and Bad Cholesterol for Athletes

Related comparison

Total Cholesterol vs Non-HDL Cholesterol: Which Matters More?